These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12537516)

  • 41. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
    Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
    Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized crossover study investigating the influence of ranitidine or omeprazole on the pharmacokinetics of cephalexin monohydrate.
    Madaras-Kelly K; Michas P; George M; May MP; Adejare A
    J Clin Pharmacol; 2004 Dec; 44(12):1391-7. PubMed ID: 15545310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine.
    Basit AW; Podczeck F; Newton JM; Waddington WA; Ell PJ; Lacey LF
    Pharm Res; 2002 Sep; 19(9):1368-74. PubMed ID: 12403075
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats.
    Lee HT; Lee YJ; Chung SJ; Shim CK
    Res Commun Mol Pathol Pharmacol; 2000; 108(5-6):311-23. PubMed ID: 11958284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regional gastrointestinal absorption of ranitidine in the rat.
    Suttle AB; Brouwer KL
    Pharm Res; 1995 Sep; 12(9):1311-5. PubMed ID: 8570527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females.
    Ashiru DA; Patel R; Basit AW
    Pharm Res; 2008 Oct; 25(10):2327-33. PubMed ID: 18600434
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral bioavailability of nizatidine and ranitidine concurrently administered with antacid.
    Desager JP; Harvengt C
    J Int Med Res; 1989; 17(1):62-7. PubMed ID: 2565267
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
    Small DS; Farid NA; Li YG; Ernest CS; Payne CD; Salazar DE; Winters KJ
    Curr Med Res Opin; 2008 Aug; 24(8):2251-7. PubMed ID: 18786302
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stereoselective pharmacokinetics of chlorpheniramine and the effect of ranitidine.
    Koch KM; O'Connor-Semmes RL; Davis IM; Yin Y
    J Pharm Sci; 1998 Sep; 87(9):1097-100. PubMed ID: 9724561
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effects of ranitidine on pharmacokinetics of rhein from Dachengqi Decoction in rats after oral administration].
    Ren YY; Gong HL; Tang WF; Wan MF; Huang X
    Zhong Xi Yi Jie He Xue Bao; 2009 Sep; 7(9):868-72. PubMed ID: 19747444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative bioavailability of two oral formulations of ranitidine.
    Flores-Murrieta FJ; Toledo A; del Carmen Carrasco-Portugal M; Reyes-García G; Rodríguez-Silverio J; Medina-Santillán R; Herrera JE
    Biopharm Drug Dispos; 2006 Jan; 27(1):23-7. PubMed ID: 16278926
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.
    Kubitza D; Becka M; Zuehlsdorf M; Mueck W
    J Clin Pharmacol; 2006 May; 46(5):549-58. PubMed ID: 16638738
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gastrokinetic activity of Morinda citrifolia aqueous fruit extract and its possible mechanism of action in human and rat models.
    Nima S; Kasiwong S; Ridtitid W; Thaenmanee N; Mahattanadul S
    J Ethnopharmacol; 2012 Jul; 142(2):354-61. PubMed ID: 22580040
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of a glucose appearance function from foods using deconvolution.
    Yates TL; Fletcher LR
    IMA J Math Appl Med Biol; 2000 Jun; 17(2):169-84. PubMed ID: 10994512
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Time-dependent oral absorption models.
    Higaki K; Yamashita S; Amidon GL
    J Pharmacokinet Pharmacodyn; 2001 Apr; 28(2):109-28. PubMed ID: 11381566
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sensitive high-performance thin-layer chromatography method for detection and determination of ranitidine in plasma samples.
    Mody VD; Satia MC; Gandhi TP; Modi IA; Modi RI; Chakravarthy BK
    J Chromatogr B Biomed Appl; 1996 Feb; 676(1):175-9. PubMed ID: 8852060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function.
    Metsugi Y; Miyaji Y; Ogawara K; Higaki K; Kimura T
    Pharm Res; 2008 Apr; 25(4):886-95. PubMed ID: 17955185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modelling ciclosporin double-peak absorption profiles in the early post-transplantation period.
    Rousseau A; Marquet P
    Clin Pharmacokinet; 2004; 43(14):1055-7. PubMed ID: 15530133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.